| Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease |
69 |
| The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases |
44 |
| Lysosome trafficking and signaling in health and neurodegenerative diseases |
33 |
| Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic updates brain injury |
32 |
| Epilepsy biomarkers - Toward etiology and pathology specificity |
27 |
| Mechanisms of selective autophagy and mitophagy: Implications for neurodegenerative diseases |
24 |
| Distinct alpha-Synuclein strains and implications for heterogeneity among alpha-Synucleinopathies |
23 |
| Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease |
22 |
| Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease |
22 |
| Alterations in cortical interneurons and cognitive function in schizophrenia |
22 |
| Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble alpha-synuclein in neurons |
21 |
| Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology |
20 |
| Pathogenesis and pathophysiology of functional (psychogenic) movement disorders |
20 |
| Autophagy and mitophagy in ALS |
20 |
| TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities |
20 |
| Translation-relevant EEG phenotypes in a mouse Syndrome |
19 |
| Beta bursts during continuous movements accompany the velocity decrement in Parkinson's disease patients |
18 |
| Prion-like seeding and nucleation of intracellular amyloid-beta |
17 |
| Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models |
17 |
| Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation |
17 |
| The role of monogenic genes in idiopathic Parkinson's disease |
16 |
| Beta burst coupling across the motor circuit in Parkinson's disease |
16 |
| Roles for neuronal and glial autophagy in synaptic pruning during development |
16 |
| Aging, lifestyle and dementia |
15 |
| Distinct cytokine profiles in human brains resilient to Alzheimer's pathology |
15 |
| Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease |
15 |
| Status epilepticus triggers long-lasting activation of complement C1q-C3 signaling in the hippocampus that correlates with seizure frequency in experimental epilepsy |
15 |
| Affective, neurocognitive and psychosocial disorders associated with traumatic brain injury and post-traumatic epilepsy |
14 |
| A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility |
14 |
| Decline in Sirtuin-1 expression and activity plays a critical role in blood-brain barrier permeability in aging |
14 |
| RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes |
14 |
| Mitochondria and neuroprotection in stroke: Cationic arginine-rich peptides (CARPs) as a novel class of mitochondria-targeted neuroprotective therapeutics |
14 |
| Internalization, axonal transport and release of fibrillar forms of alpha-synuclein |
14 |
| Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events |
14 |
| A role for autophagy in Huntington's disease |
14 |
| Emerging roles of extracellular vesicles in neurodegenerative disorders |
13 |
| Axl activation attenuates neuroinflammation by inhibiting the TLR/TRAF/NF-kappa B pathway after MCAO in rats |
13 |
| Synchronised spiking activity underlies phase amplitude coupling in the subthalamic nucleus of Parkinson's disease patients |
13 |
| Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia |
13 |
| Neurotoxic astrocytes express the D-serine synthesizing enzyme, serine racemase, in Alzheimer's disease |
13 |
| Gallic acid disruption of A beta(1-42) aggregation rescues cognitive decline of APP/PS1 double transgenic mouse |
12 |
| Preclinical development of a high affinity alpha-synuclein antibody, MEDI that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo |
12 |
| Age-dependent neurodegeneration and organelle transport deficiencies in mutant TDP43 patient-derived neurons are independent of TDP43 aggregation |
12 |
| Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction |
12 |
| Novel E815K knock-in mouse model of alternating hemiplegia of childhood |
12 |
| A beta propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease |
12 |
| Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease |
12 |
| Bexarotene protects against neurotoxicity partially through a PPAR gamma-dependent mechanism in mice following traumatic brain injury |
12 |
| Poly-ubiquitin profile in Alzheimer disease brain |
12 |
| Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study |
12 |
